Scinai Immunotherapeutics (NASDAQ:SCNI) Releases Earnings Results

Scinai Immunotherapeutics (NASDAQ:SCNI) announced its quarterly earnings results on Wednesday. The company reported $0.94 earnings per share (EPS) for the quarter, Zacks reports.

Scinai Immunotherapeutics Trading Down 7.7%

Shares of SCNI stock opened at $0.33 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.30 and a quick ratio of 1.30. The company has a market cap of $1.29 million, a price-to-earnings ratio of -0.03 and a beta of 2.05. The stock has a 50 day simple moving average of $0.54 and a 200-day simple moving average of $0.74. Scinai Immunotherapeutics has a 1-year low of $0.31 and a 1-year high of $3.48.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. Institutional investors own 58.41% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.